GNI Group Ltd
TSE:2160
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 544
3 805
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
GNI Group Ltd
GNI Group Ltd
Total Current Liabilities
GNI Group Ltd
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
GNI Group Ltd
TSE:2160
|
Total Current Liabilities
¥10.9B
|
CAGR 3-Years
68%
|
CAGR 5-Years
32%
|
CAGR 10-Years
47%
|
|
|
PeptiDream Inc
TSE:4587
|
Total Current Liabilities
¥16.8B
|
CAGR 3-Years
81%
|
CAGR 5-Years
68%
|
CAGR 10-Years
67%
|
|
|
Takara Bio Inc
TSE:4974
|
Total Current Liabilities
¥7.8B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
8%
|
CAGR 10-Years
5%
|
|
|
Pharma Foods International Co Ltd
TSE:2929
|
Total Current Liabilities
¥23.2B
|
CAGR 3-Years
28%
|
CAGR 5-Years
58%
|
CAGR 10-Years
60%
|
|
|
S
|
StemRIM Inc
TSE:4599
|
Total Current Liabilities
¥67.5m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
C
|
Cuorips Inc
TSE:4894
|
Total Current Liabilities
¥166m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
GNI Group Ltd
Glance View
GNI Group Ltd. engages in the development, research, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 629 full-time employees. The company went IPO on 2007-08-31. The firm is engaged in the development of therapeutic agents for diseases that have many sufferers in Asian countries such as Japan and China, as well as clinical trial and bio-verification test businesses. The company is engaged in research and development of therapeutic agents, including F647 for radiation pneumonia (RP) and idiopathic pulmonary fibrosis (IPF), F351 for liver fibrosis (cirrhosis) and F573 for acute hepatic insufficiency and acute chronic liver failure (ACLF).
See Also
What is GNI Group Ltd's Total Current Liabilities?
Total Current Liabilities
10.9B
JPY
Based on the financial report for Jun 30, 2024, GNI Group Ltd's Total Current Liabilities amounts to 10.9B JPY.
What is GNI Group Ltd's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
47%
Over the last year, the Total Current Liabilities growth was 140%. The average annual Total Current Liabilities growth rates for GNI Group Ltd have been 68% over the past three years , 32% over the past five years , and 47% over the past ten years .
You don't have any saved screeners yet
